 Translate Bio Inc NASDAQ: TBIO revealed its second interim analysis from Phase 12 clinical trial evaluating MRT5005 in patients with cystic fibrosis CF. MRT5005 is an mRNA product candidate designed to address CFs underlying cause by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator CFTR protein to the lung epithelial cells through nebulization. 